This study enrolled 102 patients from different ethnic minorities who were diagnosed with hepatitis C (with positive serum anti-HCV) at the Second Hospital of Dalian Medical University, Anshan Central Hospital, and the Second People's Hospital of Fuxin City between November 2011 and November 2019. Investigators obtained informed consent before enrolling participants into this study. All patients met the diagnostic criteria of the Guidelines for the Prevention and Treatment of Hepatitis C, which was formulated by the Chinese Society of Hepatology and Society of Infectious Diseases.[7] The study was approved by the Research Ethics Committee of Dalian Medical University, Liaoning, China. All patients provided written informed consent.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.